KRT13 and neoplasm: The resulting organoids retained histopathological and molecular features of primary tumor tissue; tumor cells in their composition expressed CK13 and p63, and a genetic study revealed mutations in the tumor-associated genes TP53 (in 63% of organoids), NOTCH1, PIK3CA, FAT1, and APOB, gains of oncogenes including PIK3CA, FGF3, and FGF4, and loss of tumor suppressor CDKN2A.